To translate these studies into CRC clinical therapies, there is a need for RCTs that aim to develop standardized formulations and dosage regimens of β-glucan derived from different sources and explore the interaction between β-glucan and current CRC therapies to examine the synergistic or antagonistic effects as well as its long-term effects and safety profiles. The gene discussed is PPIB; the disease is colorectal carcinoma.